• Publications
  • Influence
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
BACKGROUND The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studiedExpand
  • 594
  • 17
  • PDF
Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure.
BACKGROUND The candidate malaria vaccine RTS,S/AS01E has entered phase 3 trials, but data on long-term outcomes are limited. METHODS For 4 years, we followed children who had been randomlyExpand
  • 219
  • 13
  • PDF
Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya
Philip Bejon and colleagues document the clustering of malaria episodes and malarial parasite infection. These patterns may enable future prediction of hotspots of malaria infection and targeting ofExpand
  • 206
  • 11
  • PDF
Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.
BACKGROUND The candidate malaria vaccine RTS,S/AS01 is being evaluated in order to inform a decision regarding its inclusion in routine vaccination schedules. METHODS We conducted 7 years ofExpand
  • 187
  • 10
The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection
Vaccination with the pre-erythrocytic malaria vaccine RTS,S induces high levels of antibodies and CD4+ T cells specific for the circumsporozoite protein (CSP). Using a biologically-motivatedExpand
  • 127
  • 5
  • PDF
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
BACKGROUND An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries. METHODS From March 2009Expand
  • 473
  • 4
  • PDF
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
BACKGROUND Plasmodium falciparum malaria is a pressing global health problem. A previous study of the malaria vaccine RTS,S (which targets the circumsporozoite protein), given with an adjuvant systemExpand
  • 395
  • 4
  • PDF
Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria
Background RTS,S/AS01E is the lead candidate pre-erythrocytic malaria vaccine. In Phase IIb field trials the safety profile was acceptable and the efficacy was 53% (95%CI 31%–72%) for protectingExpand
  • 85
  • 4
  • PDF
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled
Summary Background RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against clinical falciparum malaria in 5–17 month old children, during an average of 8 monthsExpand
  • 156
  • 3
  • PDF
Characteristics and outcome of cardiopulmonary resuscitation in hospitalised African children☆
Objective To review the characteristics and outcome of cardiopulmonary resuscitation in children at a rural hospital in Kenya. Patients and method All children aged 0–14 years who experienced ≥1Expand
  • 29
  • 3
  • PDF